Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

76393

registered interest
date	08/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Heart Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to improve the medical care for patients suffering from heart disease.
tabling member constituency	Upper Bann
tabling member printed	David Simpson
uin	204512
answer	answer is ministerial correction date of answer 15/07/2014 answer text <p>The Cardiovascular Disease Outcomes Strategy, published in March 2013, sets out actions to improve outcomes for patients with cardiovascular disease, including heart disease.</p><p> </p><p>The Strategy recommends that clinical commissioning groups (CCGs) use National Institute for Health and Care Excellence (NICE) guidelines and NICE Quality Standards to help inform their commissioning intentions in this area. CCGs are being encouraged to implement the Strategy with the support of the 12 Strategic Clinical Networks.</p><p> </p><p>In addition, in December 2013, NHS England published a web based resource, <em>Our Ambition to Reduce Premature Mortality: A resource to support commissioners in setting a level of ambition<sup>1</sup>, </em>to support CCGs in reducing premature mortality and to inform production of their 2 and 5 year strategic plans for improving health outcomes in their own areas. The web based resource encompasses a range of evidence-based clinical interventions, many of which are linked to the actions in the Strategy.</p><p><strong> </strong></p><p>NHS Improving Quality is also focussing its work on the major causes of premature death, including heart disease.</p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 15/07/2014 15:56:10 answering member 3918 label Biography information for Jane Ellison
tabling member	1597 label Biography information for David Simpson

64778

registered interest
date	30/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Heart Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 26 June 2014, Official Report, column 279W, on heart diseases, how the budget of £16.9 million for Commissioning through Evaluation announced by NHS England on 6 March 2014 is being allocated between each of the five technologies within the programme.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	203096
answer	answer is ministerial correction date of answer 07/07/2014 answer text <p>We understand from NHS England that the budget for Commissioning through Evaluation is being allocated as follows:</p><p> </p><p>- £9 million for three interventional cardiology schemes;</p><p>- £4.8 million for selective internal radiation therapy; and</p><p>- £1.6 million for selective dorsal rhizotomy.</p><p><strong> </strong></p><p>£1.5 million has been removed from the budget as the renal denervation scheme is no longer being progressed. This is due to recently available research findings.</p><p><strong> </strong></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 07/07/2014 14:36:30 answering member 3918 label Biography information for Jane Ellison
tabling member	1506 label Biography information for Andrew Gwynne

64118

registered interest
date	25/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Heart Diseases
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what action they are taking to improve the diagnosis of atrial fibrillation.
tabling member printed	Lord Black of Brentwood
uin	HL622
answer	answer is ministerial correction date of answer 08/07/2014 answer text <p>NHS England is taking a number of actions to improve the care and management of people with atrial fibrillation (AF). It has published <em>Our Ambition to Reduce Premature Mortality: A resource to support commissioners in setting a level of ambition</em>, which identifies improved management of AF as a priority for reducing premature mortality. The resource can be found at:</p><p> </p><p>www.england.nhs.uk/ourwork/sop/red-prem-mort/</p><p> </p><p>National Health Service Improving Quality's <em>Living Longer Lives</em> programme includes promoting the use of a simple but effective audit tool called Guidance on Risk Assessment and Stroke Prevention for Atrial Fibrillation (GRASP-AF) which simplifies the process of identifying patients with AF who are not receiving the right treatment. NHS Improving Quality is currently collaborating with partner organisations, including charities, to support the nationwide roll-out of GRASP-AF.</p><p> </p><p>This work will be supported by the publication of an economic analysis commissioned by NHS Improving Quality using GRASP data which demonstrates both the current and potential impact of atrial fibrillation management on the number of AF related strokes.</p><p><em> </em></p><p>Discussions are also underway to consider whether opportunistic testing for atrial fibrillation (AF) should be encouraged nationally as part of the NHS Health Check programme.</p><p> </p> answering member printed Earl Howe grouped question UIN HL623 question first answered 08/07/2014 15:27:07 answering member 2000 label Biography information for Earl Howe
tabling member	4171 label Biography information for Lord Black of Brentwood

64119

registered interest
date	25/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Heart Diseases
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, in the light of the publication of the National Institute for Health and Care Excellence clinical guideline 180, what action they are taking to ensure appropriate risk stratification and uptake of anti-thrombotic therapy among patients with atrial fibrillation.
tabling member printed	Lord Black of Brentwood
uin	HL623
answer	answer is ministerial correction date of answer 08/07/2014 answer text <p>NHS England is taking a number of actions to improve the care and management of people with atrial fibrillation (AF). It has published <em>Our Ambition to Reduce Premature Mortality: A resource to support commissioners in setting a level of ambition</em>, which identifies improved management of AF as a priority for reducing premature mortality. The resource can be found at:</p><p> </p><p>www.england.nhs.uk/ourwork/sop/red-prem-mort/</p><p> </p><p>National Health Service Improving Quality's <em>Living Longer Lives</em> programme includes promoting the use of a simple but effective audit tool called Guidance on Risk Assessment and Stroke Prevention for Atrial Fibrillation (GRASP-AF) which simplifies the process of identifying patients with AF who are not receiving the right treatment. NHS Improving Quality is currently collaborating with partner organisations, including charities, to support the nationwide roll-out of GRASP-AF.</p><p> </p><p>This work will be supported by the publication of an economic analysis commissioned by NHS Improving Quality using GRASP data which demonstrates both the current and potential impact of atrial fibrillation management on the number of AF related strokes.</p><p><em> </em></p><p>Discussions are also underway to consider whether opportunistic testing for atrial fibrillation (AF) should be encouraged nationally as part of the NHS Health Check programme.</p><p> </p> answering member printed Earl Howe grouped question UIN HL622 question first answered 08/07/2014 15:27:07 answering member 2000 label Biography information for Earl Howe
tabling member	4171 label Biography information for Lord Black of Brentwood

63505

registered interest
date	24/06/2014
answering body	Cabinet Office
answering dept id	53
answering dept short name	Cabinet Office
answering dept sort name	Cabinet Office
hansard heading	Heart Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Minister for the Cabinet Office, how many people died of congenital heart disease below the age of 40 years in each region and constituent part of the UK in each of the last 15 years.
tabling member constituency	Vale of Clwyd
tabling member printed	Chris Ruane
uin	202131
answer	answer is ministerial correction date of answer 30/06/2014 answer text <p>The information requested falls within the responsibility of the UK Statistics Authority. I have asked the Authority to reply.</p><p> </p> answering member constituency Ruislip, Northwood and Pinner answering member printed Mr Nick Hurd question first answered 30/06/2014 16:37:49 answering member 1561 label Biography information for Mr Nick Hurd attachment 1 file name PQ202131.pdf title ONS Letter to Member
tabling member	534 label Biography information for Chris Ruane

63675

registered interest
date	24/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Heart Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many (a) adults and (b) children in each region and constituent part of the UK suffer from congenital heart disease.
tabling member constituency	Vale of Clwyd
tabling member printed	Chris Ruane
uin	202136
answer	answer is ministerial correction date of answer 01/07/2014 answer text <p>The Department has made no assessment of the efficacy and potential cost-savings to the National Health Service of self-monitoring machines for blood testing for sufferers of congenital heart disease.</p><p> </p><p>Under its diagnostics assessment programme, the National Institute for Health and Care Excellence (NICE) is developing guidance on two diagnostic technologies for patients on anticoagulation treatments to self-monitor their coagulation status. We understand that NICE expects to issue guidance in August 2014.</p><p> </p><p>Information is not collected centrally on the number of adults and children in the United Kingdom who suffer from congenital heart disease.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 202130 question first answered 01/07/2014 13:04:31 answering member 3918 label Biography information for Jane Ellison
tabling member	534 label Biography information for Chris Ruane

63677

registered interest
date	24/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Heart Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the availability of free prescriptions for congenital heart disease across England.
tabling member constituency	Vale of Clwyd
tabling member printed	Chris Ruane
uin	202129
answer	answer is ministerial correction date of answer 01/07/2014 answer text <p>No assessment has been made of the availability of free prescriptions for people with congenital heart disease in England.</p><p> </p><p>The list of medical conditions that give entitlement to apply for an National Health Service prescription charge medical exemption certificate are:</p><p> </p><p>- a permanent fistula (including caecostomy, colostomy, laryngostomy, or ileostomy) which requires continuous surgical dressing or requires an appliance;</p><p>- forms of hypoadrenalism (including Addison's disease) for which specific substitution therapy is essential;</p><p>- diabetes insipidus or other forms of hypopituitarism;</p><p>- diabetes mellitus (except where treatment of the diabetes is by diet alone);</p><p>- hypoparathyroidism;</p><p>- myasthenia gravis;</p><p>- myxoedema (that is, hypothyroidism requiring thyroid hormone replacement);</p><p>- epilepsy requiring continuous anti-convulsive therapy;</p><p>- continuing physical disability which prevents the patient from leaving their residence without the help of another person; and</p><p>- patients undergoing treatment for cancer, the effects of cancer or the effects of current or previous cancer treatment.</p><p> </p><p>All other medical conditions do not entitle patients to apply for an NHS prescription charge medical exemption certificate.</p><p> </p><p>The extensive system of exemption arrangements, including for those on low incomes who may struggle to pay for their prescriptions, which is in place means that around 90% of all prescription items are already dispensed free of charge. Prescription Prepayment Certificates are also available for those who have to pay NHS prescription charges and need multiple prescriptions.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 202137 question first answered 01/07/2014 14:43:04 answering member 1439 label Biography information for Norman Lamb
tabling member	534 label Biography information for Chris Ruane

63679

registered interest
date	24/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Heart Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the efficacy and potential cost-savings to the NHS of self-monitoring machines for blood testing for sufferers of congenital heart disease.
tabling member constituency	Vale of Clwyd
tabling member printed	Chris Ruane
uin	202130
answer	answer is ministerial correction date of answer 01/07/2014 answer text <p>The Department has made no assessment of the efficacy and potential cost-savings to the National Health Service of self-monitoring machines for blood testing for sufferers of congenital heart disease.</p><p> </p><p>Under its diagnostics assessment programme, the National Institute for Health and Care Excellence (NICE) is developing guidance on two diagnostic technologies for patients on anticoagulation treatments to self-monitor their coagulation status. We understand that NICE expects to issue guidance in August 2014.</p><p> </p><p>Information is not collected centrally on the number of adults and children in the United Kingdom who suffer from congenital heart disease.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 202136 question first answered 01/07/2014 13:04:31 answering member 3918 label Biography information for Jane Ellison
tabling member	534 label Biography information for Chris Ruane

62932

registered interest
date	19/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Heart Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many patients and for how many years NHS England plans to recruit into each of the complex invasive cardiology Commissioning through Evaluation projects.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	201562
answer	answer is ministerial correction date of answer 26/06/2014 answer text <p>NHS England is currently progressing three commissioning through evaluation (CtE) schemes relating to invasive cardiology. A maximum full year annual budget of £9 million has been allocated, but the period of budget allocation will depend on the final length of the schemes themselves, which will be tailored with the assistance of National Institute for Health Care Excellence (NICE) to capture sufficient evaluative data over the scheme period.</p><p> </p><p>NHS England has allocated funding to each of the schemes based on early estimates of patient numbers and the key evaluative questions to be answered by the end of each scheme. Patient numbers will need to be contained within these parameters.</p><p> </p><p>NHS England is currently assessing a significant number of applications from providers who have expressed an interest in acting as a participating centre in each of the three schemes. Once this process is complete, and the selected centres are confirmed, we will be able to complete contractual arrangements and confirm a ‘go live' date with each centre. Unfortunately we are therefore unable to give a specific date for patient recruitment to start at this stage.</p><p> </p><p>NHS England expects CtE schemes to typically run for two to three years but the final length of each of the invasive cardiology schemes is not yet finalised as they are being tailored with the assistance of NICE to capture sufficient evaluative data over the scheme period. The length of the schemes may also be influenced by early findings from the evaluation or by the publication of research data exploring similar parameters. The numbers of patients to be seen by each of the schemes is not yet finalised since it will depend on the final tariff negotiated with participating providers, and the length of each scheme.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 201479 201540 201561 question first answered 26/06/2014 14:30:39 answering member 3918 label Biography information for Jane Ellison
tabling member	1506 label Biography information for Andrew Gwynne

62933

registered interest
date	19/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Heart Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what funding has been allocated to each of the invasive cardiology Commissioning through Evaluation projects in each of the next five years.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	201540
answer	answer is ministerial correction date of answer 26/06/2014 answer text <p>NHS England is currently progressing three commissioning through evaluation (CtE) schemes relating to invasive cardiology. A maximum full year annual budget of £9 million has been allocated, but the period of budget allocation will depend on the final length of the schemes themselves, which will be tailored with the assistance of National Institute for Health Care Excellence (NICE) to capture sufficient evaluative data over the scheme period.</p><p> </p><p>NHS England has allocated funding to each of the schemes based on early estimates of patient numbers and the key evaluative questions to be answered by the end of each scheme. Patient numbers will need to be contained within these parameters.</p><p> </p><p>NHS England is currently assessing a significant number of applications from providers who have expressed an interest in acting as a participating centre in each of the three schemes. Once this process is complete, and the selected centres are confirmed, we will be able to complete contractual arrangements and confirm a ‘go live' date with each centre. Unfortunately we are therefore unable to give a specific date for patient recruitment to start at this stage.</p><p> </p><p>NHS England expects CtE schemes to typically run for two to three years but the final length of each of the invasive cardiology schemes is not yet finalised as they are being tailored with the assistance of NICE to capture sufficient evaluative data over the scheme period. The length of the schemes may also be influenced by early findings from the evaluation or by the publication of research data exploring similar parameters. The numbers of patients to be seen by each of the schemes is not yet finalised since it will depend on the final tariff negotiated with participating providers, and the length of each scheme.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 201479 201561 201562 question first answered 26/06/2014 14:30:39 answering member 3918 label Biography information for Jane Ellison
tabling member	1506 label Biography information for Andrew Gwynne